Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "Greece Construction Market Size, Trends, and Forecasts by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and...
-
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing...
-
Las Vegas, May 13, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: The top reasons weight loss supplements fail and why most solutions don’t address both day and night fat-burning...
-
New York, May 08, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover: Why do many researchers struggle to find high-quality SARMs and peptides for sale in the USAThe most common pitfalls...
-
Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash...
-
Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Major Depressive Disorder - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. This report offers an extensive examination...
-
Austin, May 05, 2025 (GLOBE NEWSWIRE) -- Acromegaly Treatment Market Trends & Growth Analysis: According to SNS Insider, the global acromegaly treatment market was valued at USD 1.76 billion...
-
New York City, April 30, 2025 (GLOBE NEWSWIRE) -- Introduction: Why Testosterone Support Matters After 40 As men age, maintaining strength, stamina, and masculinity becomes increasingly difficult...
-
DUBAI, United Arab Emirates, April 28, 2025 (GLOBE NEWSWIRE) -- In a landmark move, Faculty Group and Ghaf Capital today announced their merger to form Ghaf Group, a vertically integrated Web3...
-
TAIPEI, Taïwan, 24 avr. 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx : 4174. TWO) a communiqué aujourd’hui des données non cliniques sur OBI-902, un CAM anti-TROP2 potentiellement le...